Program
Oncolytic Virus M1-c6v1
Also written as “VRT106”, “VRT106 for injection” and “VRT106 in combination with camrelizumab and apatinib”.
Its studies are mostly in Diffuse Intrinsic Pontine Glioma · Glioblastoma, led by Guangzhou Virotech Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Guangzhou Virotech Pharmaceutical | 66 open or running | phase 3since May 8, 2026 | Sep 12, 2023 | Sep 2027phase 1 · NCT06368921 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 12, 2023First study: phase 1 study in Solid TumorFirst studyNCT06046742 · 12 planned · Japan
- Apr 9, 2024Phase 1 study in Solid TumorNCT06368921 · 30 planned · China
- Feb 10, 2025Phase 1 study in Solid TumorsNCT06826313 · 12 planned · China
- Jul 15, 2025Phase 2 study in GlioblastomaNCT07093814 · 42 planned · China
- May 8, 2026Phase 2 study in Diffuse Intrinsic Pontine GliomaNCT07589257 · 10 planned · China
- May 8, 2026Phase 3 study in HCCPhase 3 reachedNCT07589244 · 66 planned · China
Ahead
- Sep 2027Primary completion: phase 1 study in Solid TumorNCT06368921
- Jun 30, 2028Primary completion: phase 2 study in Diffuse Intrinsic Pontine GliomaNCT07589257
- Jun 30, 2028Primary completion: phase 1 study in Solid TumorNCT06046742
- Dec 30, 2028Primary completion: phase 1 study in Solid TumorsNCT06826313
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07589257Diffuse Intrinsic Pontine Glioma · China | 2 | Recruiting | Jun 30, 2028 | 10 |
| NCT07589244HCC · China | 3 | Recruiting | Dec 31, 2028 | 66 |
| NCT07093814Glioblastoma · China | 2 | Recruiting | Dec 31, 2028 | 42 |
| NCT06826313Solid Tumors · China | 1 | Recruiting | Dec 30, 2028 | 12 |
| NCT06368921Solid Tumor · China | 1 | Recruiting | Sep 2027 | 30 |
| NCT06046742Solid Tumor · Japan | 1 | Recruiting | Jun 30, 2028 | 12 |
How it is read
Names in the registry
- “VRT106”, 4 entries
- “VRT106 for injection”, 1 entry
- “VRT106 in combination with camrelizumab and apatinib”, 1 entry
- “M1-c6v1”, 1 entry
Conditions, from the studies’ own filings
- Diffuse Intrinsic Pontine Glioma, 1 study
- Glioblastoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.